https://www.selleckchem.com/pr....oducts/lificiguat-yc
5% of hepatic recurrences, and the median OS was significantly higher than for patients treated with systemic treatment alone (P0.001). Combining hepatectomy and IORFA could provide comparable survival rates for patients with multiple unresectable CRLM compared to those with resectable CRLM treated with hepatectomy alone. Combining hepatectomy and IORFA could provide comparable survival rates for patients with multiple unresectable CRLM compared to those with resectable CRLM treated with hepatectomy alone. While a certain de